Bristol Myers Squibb - U.S. Food and Drug Administration …
WEB4 days ago · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. 1 COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating ...
Bristol Myers wins US FDA approval for new type of ... - Yahoo
WEB3 days ago · By Bhanvi Satija and Michael Erman. (Reuters) -The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of ...
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets …
WEB3 days ago · Bristol Myers Squibb shares surged in premarket trading and were up 2% about 30 minutes into Friday's session, but remain slightly negative for 2024. TradingView Read the original article on ...
Bristol Myers (BMY) Gets US Nod for First New Schizophrenia …
WEB3 days ago · Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh avenue of treatment for millions with the serious mental disorder.
FDA approves Bristol Myers Squibb's schizophrenia drug
WEB4 days ago · The Food and Drug Administration approved Bristol Myers Squibb's highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more than ...
Bristol Myers Squibb - News
WEBSep 18, 2024 · Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
Pharmaceutical press releases & news - Bristol Myers Squibb
WEBSep 10, 2024 · Explore Bristol Myers Squibb's latest press releases to learn more about our company, our medicines and research innovation, our partnerships, our people, and our Foundation efforts as we work to support patients fighting serious disease.
Bristol Myers Squibb - Bristol Myers Squibb Completes …
WEBMar 18, 2024 · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”).
Bristol Myers second-quarter results beat expectations, helped by …
WEBJul 26, 2024 · Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its...
Bristol-Myers Squibb stock jumps on schizophrenia drug approval
WEB3 days ago · Bristol-Myers Squibb shares rose in premarket trade on Friday after the U.S. Food and Drug Administration approved a schizophrenia drug. Bristol-Myers shares BMY jumped 6% to a five-month high in ...